NCT02786732View on ClinicalTrials.gov

Study to Evaluate Broadlumab vs Placebo and Ustekinumab

PHASE3TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

June 30, 2017

Study Completion Date

October 31, 2017

Conditions
Psoriasis
Interventions
BIOLOGICAL

210mg Brodalumab

Brodalumab 210mg administered subcutaneously

BIOLOGICAL

140mg Brodalumab

Brodalumab 140mg administered subcutaneously

BIOLOGICAL

Ustekinumab

Ustekinumab 45mg or 90mg adminstered subcutaneously

BIOLOGICAL

Placebo

Placebo administered subcutaneously

Trial Locations (1)

92103

MedDerm Associates, San Diego

Sponsors

Lead Sponsor

MedDerm Associates
All Listed Sponsors
lead

MedDerm Associates

INDUSTRY

NCT02786732 - Study to Evaluate Broadlumab vs Placebo and Ustekinumab | Biotech Hunter | Biotech Hunter